
    
      This is a randomized, double-blind, placebo-controlled study that will assess the safety,
      efficacy, and pharmacokinetics (PK) of miricorilant in obese patients with schizophrenia who
      are currently taking olanzapine, risperidone, paliperidone, or quetiapine.

      Patients who meet the criteria for the Study CORT118335-877 will be randomized on Day 1 to
      receive 600 mg miricorilant, 900 mg miricorilant, or placebo for 26 weeks.
    
  